These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35952942)

  • 41. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis.
    Önal İK; Beyazit Y; Şener B; Savuk B; Özer Etık D; Sayilir A; Öztaş E; Torun S; Özderın Özın Y; Tunç Demırel B; Ülker A; Dağli Ü
    Turk J Gastroenterol; 2012; 23(5):509-14. PubMed ID: 23161295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The patient simple clinical colitis activity index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: a comparison of the P-SCCAI with clinician-based SCCAI and biological markers.
    Bennebroek Evertsz' F; Nieuwkerk PT; Stokkers PC; Ponsioen CY; Bockting CL; Sanderman R; Sprangers MA
    J Crohns Colitis; 2013 Dec; 7(11):890-900. PubMed ID: 23269224
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
    Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
    Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does colonoscopy cause increased ulcerative colitis symptoms?
    Menees S; Higgins P; Korsnes S; Elta G
    Inflamm Bowel Dis; 2007 Jan; 13(1):12-8. PubMed ID: 17206634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease.
    Amati L; Passeri ME; Selicato F; Mastronardi ML; Penna A; Jirillo E; Covelli V
    Immunopharmacol Immunotoxicol; 2006; 28(4):665-81. PubMed ID: 17190742
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time-to-reach Target Calprotectin Level in Newly Diagnosed Patients With Inflammatory Bowel Disease.
    Haisma SM; Verkade HJ; Scheenstra R; van der Doef HPJ; Bodewes FAJA; van Rheenen PF
    J Pediatr Gastroenterol Nutr; 2019 Oct; 69(4):466-473. PubMed ID: 31365486
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission.
    Garcia-Planella E; Mañosa M; Chaparro M; Beltrán B; Barreiro-de-Acosta M; Gordillo J; Ricart E; Bermejo F; García-Sánchez V; Piqueras M; Llaó J; Gisbert JP; Cabré E; Domènech E;
    Scand J Gastroenterol; 2018 Feb; 53(2):152-157. PubMed ID: 29189092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes.
    Schoepfer AM; Beglinger C; Straumann A; Trummler M; Renzulli P; Seibold F
    Inflamm Bowel Dis; 2009 Dec; 15(12):1851-8. PubMed ID: 19462421
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis.
    Osterman MT; Aberra FN; Cross R; Liakos S; McCabe R; Shafran I; Wolf D; Hardi R; Nessel L; Brensinger C; Gilroy E; Lewis JD;
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1887-93.e3. PubMed ID: 24793028
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Symptoms Do Not Correlate With Findings From Colonoscopy in Children With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.
    Ricciuto A; Fish J; Carman N; Walters TD; Church PC; Hansen BE; Crowley E; Siddiqui I; Nguyen GC; Kamath BM; Griffiths AM
    Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1098-1105.e1. PubMed ID: 29378308
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Microbial and Metabolite Signatures of Stress Reactivity in Ulcerative Colitis Patients in Clinical Remission Predict Clinical Flare Risk.
    Jacobs JP; Sauk JS; Ahdoot AI; Liang F; Katzka W; Ryu HJ; Khandadash A; Lagishetty V; Labus JS; Naliboff BD; Mayer EA
    Inflamm Bowel Dis; 2024 Mar; 30(3):336-346. PubMed ID: 37650887
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
    Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
    J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy.
    Yamamoto T; Shiraki M; Bamba T; Umegae S; Matsumoto K
    Int J Colorectal Dis; 2014 Apr; 29(4):485-91. PubMed ID: 24343276
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of Fecal Calprotectin as a Noninvasive Indicator for Ulcerative Colitis Disease Activity.
    Nakov RV; Nakov VN; Gerova VA; Tankova LT
    Folia Med (Plovdiv); 2019 Jun; 61(2):188-196. PubMed ID: 31301663
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
    Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
    Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients.
    Lin WC; Wong JM; Tung CC; Lin CP; Chou JW; Wang HY; Shieh MJ; Chang CH; Liu HH; Wei SC;
    World J Gastroenterol; 2015 Dec; 21(48):13566-73. PubMed ID: 26730169
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
    Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. High Dietary Intake of Specific Fatty Acids Increases Risk of Flares in Patients With Ulcerative Colitis in Remission During Treatment With Aminosalicylates.
    Barnes EL; Nestor M; Onyewadume L; de Silva PS; Korzenik JR;
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1390-1396.e1. PubMed ID: 28110099
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases.
    Buisson A; Vazeille E; Minet-Quinard R; Goutte M; Bouvier D; Goutorbe F; Pereira B; Barnich N; Bommelaer G
    Aliment Pharmacol Ther; 2016 May; 43(10):1069-79. PubMed ID: 26953251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.